


PG4894USW

In the Claims:

1. (Previously Presented) A compound of formula (I)



or a pharmaceutically acceptable salt thereof in which:

X is selected from the group consisting of oxygen or NR²;

R¹ is selected from the group consisting of H, C₁₋₆alkyl, C₁₋₂alkyl substituted by one to five fluorine atoms, C₃₋₆alkenyl, C₃₋₆alkynyl, C₃₋₁₀cycloalkylC₀₋₆alkyl, C₄₋₁₂bridged cycloalkyl, A(CR⁵R⁶)_n and B(CR⁵R⁶)_n;

R² is selected from the group consisting of H and C₁₋₆alkyl;

R³ is C₁₋₂alkyl substituted by one to five fluorine atoms;


R⁴ is selected from the group consisting of C₁₋₆alkyl, NH₂ and R⁸CONH;

R⁵ and R⁶ are independently selected from H or C₁₋₆alkyl;

A is an unsubstituted 5- or 6-membered heteroaryl or an unsubstituted 6-membered aryl, or a 5- or 6-membered heteroaryl or a 6-membered aryl substituted by one or more R⁷;

R⁷ is selected from the group consisting of halogen, C₁₋₆alkyl, C₁₋₆alkyl substituted by one more fluorine atoms, C₁₋₆alkoxy, C₁₋₆alkoxy substituted by one or more F, NH₂SO₂ and C₁₋₆alkylSO₂;

B is selected from the group consisting of



) defines the point of attachment of the ring;


R⁸ is selected from the group consisting of H, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkylOC₁₋₆alkyl, phenyl, HO₂CC₁₋₆alkyl, C₁₋₆alkylOCOC₁₋₆alkyl,

PG4894USW

C_{1-6} alkyloCO, H_2NC_{1-6} alkyl, C_{1-6} alkyloCONHC $_{1-6}$ alkyl and
 C_{1-6} alkyloCONHC $_{1-6}$ alkyl; and


n is 0 to 4,

wherein the 5-membered heteroaryl is selected from




and

wherein the 6-membered heteroaryl is selected from



2. (Previously Presented) A compound of formula (IA)



or a pharmaceutically acceptable salt thereof in which:

R^2 is selected from the group consisting of H and C_{1-6} alkyl;

R^4 is selected from the group consisting of C_{1-6} alkyl, NH_2 and R^8CONH ;

R^5 and R^6 are independently selected from H or C_{1-6} alkyl;

A is C_{5-7} cycloalkyl or an unsubstituted 5- or 6-membered heteroaryl or an unsubstituted 6-membered aryl, or a 5- or 6-membered heteroaryl or a 6-membered aryl substituted by one or more R^7 ;


PG4894USW

R^7 is selected from the group consisting of halogen, C_{1-6} alkyl, C_{1-6} alkyl substituted by one more fluorine atoms, C_{1-6} alkoxy, C_{1-6} alkoxy substituted by one or more F, NH_2SO_2 and $C_{1-6}alkylSO_2$;

R^8 is selected from the group consisting of H, C_{1-6} alkyl, C_{1-6} alkoxy, $C_{1-6}alkylOC_{1-6}alkyl$, phenyl, $HO_2CC_{1-6}alkyl$, $C_{1-6}alkylOCOC_{1-6}alkyl$, $C_{1-6}alkylOCO$, $H_2NC_{1-6}alkyl$, $C_{1-6}alkylOCONHC_{1-6}alkyl$ and $C_{1-6}alkylCONHC_{1-6}alkyl$; and


n is 0 to 4,

wherein the 5-membered heteroaryl is selected from



and


wherein the 6-membered heteroaryl is selected from



3. (Previously Presented) A compound as claimed in claim 1 wherein R^2 is H or methyl.
4. (Previously Presented) A compound as claimed in claim 1 wherein R^4 is C_{1-3} alkyl.
5. (Previously Presented) A compound as claimed in claim 1 wherein R^5 and R^6 are both H.

PG4894USW

6. (Previously Presented) A compound as claimed in claim 1 wherein A is selected from the group consisting of C₅₋₇-cycloalkyl or



and A is unsubstituted or substituted by one or two R⁷.

7. (Previously Presented) A compound as claimed in claim 1 wherein R⁷ is selected from the group consisting of halogen, C₁₋₃alkyl, C₁₋₃alkyl substituted by one to three fluorine atoms, and C₁₋₃alkoxy.

8. (Previously Presented) A compound as claimed in claim 1 wherein R⁸ is selected from the group consisting of C₁₋₆alkyl, phenyl and aminomethyl.

9. (Previously Presented) A compound as claimed in claim 1 wherein n is 0 to 2.

10. (Canceled)

11. (Previously Presented) [4-(5-Methanesulfonyl-pyridin-2-yl)-6-trifluoromethyl-pyrimidin-2-yl]-methyl-(6-methyl-pyridin-2-yl)methyl)-amine; benzyl-[4-(5-methanesulfonyl-pyridin-2-yl)-6-trifluoromethyl-pyrimidin-2-yl]-amine; and cyclohexyl-[4-(5-methanesulfonyl-pyridin-2-yl)-6-trifluoromethyl-pyrimidin-2-yl]-amine.

PG4894USW

12. - 13. (Canceled).

14. (Previously Presented) A pharmaceutical composition comprising a compound as defined in claim 1 in admixture with one or more physiologically acceptable carriers or excipients.

15. - 19. (Canceled)

20. (Previously Presented) A pharmaceutical composition comprising a compound as defined in claim 2 in admixture with one or more physiologically acceptable carriers or excipients.

21. - 24. (Canceled).

25. (Previously Presented) A method of treating a subject suffering from dysmenorrhoea which comprises administering to said subject an effective amount of a compound as claimed in claim 1.

26. (Previously Presented) The method according to claim 25, wherein said subject is a human.

27. (Previously Presented) A method of treating a subject suffering from arthritis which comprises administering to said subject an effective amount of a compound as defined in claim 1.

28. (Previously Presented) The method according to claim 27 wherein said arthritis is rheumatoid arthritis.

29. (Previously Presented) The method according to claim 28 wherein said subject is a human.

30. (Previously Presented) A method of treating a subject suffering from osteoarthritis which comprises administering to said subject an effective amount of a compound as defined in claim 1.

PG4894USW

31. (Previously Presented) The method according to claim 30 wherein said subject is a human.
32. – 33. (Canceled).
34. (Previously Presented) A method of treating a subject suffering from dysmenorrhoea which comprises administering to said subject an effective amount of a compound as claimed in claim 2.
35. (Previously Presented) The method according to claim 34, wherein said subject is a human.
36. (Previously Presented) A method of treating a subject suffering from arthritis which comprises administering to said subject an effective amount of a compound as defined in claim 2.
37. (Previously Presented) The method according to claim 36 wherein said arthritis is rheumatoid arthritis.
38. (Previously Presented) The method according to claim 36 wherein said subject is a human.
39. (Previously Presented) A method of treating a subject suffering from osteoarthritis which comprises administering to said subject an effective amount of a compound as defined in claim 2.
40. (Previously Presented) The method according to claim 39 wherein said subject is a human.
41. – 46. (Canceled).